- Home
- TSI vs SRTS Comparison
TSI vs SRTS Comparison
Compare TSI & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSI | SRTS |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.6M | 46.9M |
| IPO Year | 1995 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TSI | SRTS |
|---|---|---|
| Price | $4.51 | $2.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 115.1K | 93.4K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,482,000.00 |
| Revenue This Year | N/A | $2.00 |
| Revenue Next Year | N/A | $34.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.43 | $2.66 |
| 52 Week High | $5.06 | $5.92 |
Technical Indicators
Market Signals| Indicator | TSI | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 25.51 |
| Support Level | $4.43 | N/A |
| Resistance Level | $4.58 | $3.35 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 5.00 | 3.25 |
Price Performance
Historical ComparisonAbout TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a diversified closed-end management investment company. The investment objective of the company is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as banks, beverages, biotechnology, chemicals, commercial services, and others.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.